<DOC>
	<DOCNO>NCT01820793</DOCNO>
	<brief_summary>Escherichia coli primary cause urinary tract infection Gram-negative bacteremia worldwide . Since early year 21st century , E.coli acquire new mechanism resistance antibiotic : extend spectrum β-lactamase ( ESBL ) , type CTX-M . These ESBL inactivate β-lactams , preferred class antibiotic treatment severe E.coli infection . Moreover , strain produce ESBL often resistant class antibiotic . Their rapid spread constitutes major public health concern serious risk therapeutic impasse . Treatment option case infection ESBL-producing E.coli often limit carbapenems , class recently develop β-lactams . Carbapenems wide spectrum activity effectiveness threaten emergence strain produce carbapenemases . The development therapeutic alternative treat ESBL-producing E.coli infection therefore essential . Cephamycins , include cefoxitin , β-lactams marketed seventy use practically abandon wide spectrum antibiotic become available . They distinguish presence α-methoxy group position 7 interferes action extended-spectrum β-lactamase render ineffective cephamycins . Cefoxitin therefore active vitro ESBL-producing E.coli offer advantage narrower antibacterial spectrum , thus reduce selection pressure emergence resistance . However , vivo activity cefoxitin treatment ESBL-producing E.coli infection never measure . Furthermore , available pharmacokinetic pharmacodynamic ( PK/PD ) data cefoxitin date incomplete , raise many question concern optimal dosage regimen . We show mouse model ESBL-producing E. coli CTX-M pyelonephritis cefoxitin efficacy comparable carbapenems without select resistant mutant . Cefoxitin could thus constitute alternative carbapenems treatment pyelonephritis cause ESBL-producing E.coli .</brief_summary>
	<brief_title>Efficacy Pharmacokinetic/Pharmacodynamic Parameters Cefoxitin Women With Acute Pyelonephritis Without Severity Symptoms Due Extended-spectrum β-lactamase Producing Escherichia Coli</brief_title>
	<detailed_description>Clinical Study : This prospective , multicentric , non-comparative , proof concept study evaluate efficacy cefoxitin woman acute ESBL-producing E. coli pyelonephritis without severity symptom . This antibiotic already commercially available tolerability profile well know , never previously evaluate treat particular type infection . The primary objective study assess clinical microbiological response treatment cefoxitin woman acute pyelonephritis without severity symptom due ESBL-producing E. coli . The secondary objective : In woman pyelonephritis cause ESBL-producing E.coli : - Gain good understand current epidemiology ESBL-producing E. coli associate febrile UTI - Assess impact cefoxitin use emergence resistance colonise bacteria gastrointestinal tract woman pyelonephritis treat cefoxitin identify associate mechanism - Characterise PK/PD parameter cefoxitin order optimise dosage strategy antibiotic - Assess tolerance profile cefoxitin Determination sample size , feasibility enrolment No determination minimal sample size could calculate proof concept study total enrolment 40 patient 8 participate center seem adequate evaluate efficacy cefoxitin treat uncomplicated acute pyelonephritis study impact emergence resistance . Half enrol woman repeat measurement serum concentration cefoxitin : 6 blood sample collect within 6 hour follow injection one dose receive 3rd last day treatment . A security assessment independent committee conduct first five patient enrol . The precise incidence ESBL-producing E.coli acute pyelonephritis without severity symptom 8 participate center unknown . At BICHAT hospital , incidence ESBL-producing E.coli 2008 0.66/100 admission ( 57 778 admissions/year ) . It 0.46/1000 hospitalisation day BEAUJON 2009 36.5 % urine sample . The year , Saint-Louis hospital record 18 bacteremia secondary infection ESBL-producing E.coli 6 % originate UTI . Those last number underestimate actual incidence ESBL-producing E coli pyelonephritis hospital , take account UTI associate bacteremia . We estimate approximately 10 case ESBL-producing E.coli pyelonephritis center year . Outline conduct study/investigations perform CIC As soon antibiogram available , confirm diagnosis ESBL-producing E. coli verification inclusion criterion , information obtention write consent , cefoxitin ( 2 gram intravenous perfusion 30 minute every 6 hour ) give 10 day . A control visit urine culture perform day 2 , day 7 end treatment , day 10 . A rectal swab perform enrolment first dose antibiotic , end treatment ( day 10 ) day 40 . The inclusion period 2 year patient 's participation last 40 day . The PK study perform 20 patient enrol one 4 CIC hospital Saint-Louis , BICHAT , HENRI-MONDOR HEGP . Measurement serum concentration cefoxitin do 3rd day treatment , 9th 12th dose antibiotic . Samples take follow : t0 ( immediately begin infuse cefoxitin ) ; t30 min ( end infusion ) ; t45 min ; t1h ; t3h ; t6h ( next dose ) total 6 sample . Evaluation criterion primary objective Clinical microbiological response define end cefoxitin treatment presence 3 follow criterion : ( ) afebrile ( temperature &gt; 36° &lt; 38°C ) , ( ii ) resolution urinary symptom present time diagnosis : dysuria , urgency , frequency , cloudy urine , pain urination , pelvic lumbar pain ( iii ) sterile urine culture . Evaluation criterion secondary objective ( ) Clinical microbiological response 48h begin treatment cefoxitin ; ( ii ) Early relapse day 40 ; ( iii ) PK/PD parameter ; ( iv ) side effect cefoxitin . Statistics , PK/PD modelling , cefoxitin dose regimen optimisation Qualitative variable report percentage study subject quantitative variable median . Comparisons use non-parametric test . The test bilateral use significance threshold 5 % . The rate clinical microbiological response end treatment cefoxitin report percentage estimate confidence interval ( CI ) 95 % ( use binomial distribution ) . PK analysis conduct use population approach average PK parameter cefoxitin estimate well interpatient variability . The PK population analysis examine different demographic clinical covariables order weigh influence PK/PD parameter ; study covariables : age , weight , BMI , blood pressure creatinine clearance . In order study relationship pharmacokinetics clinical response H48 end treatment well J40±5 , patient ' PK parameter compare use Wilcoxon Mann-Whitney non-parametric test . ESBL-producing E.coli strain responsible pyelonephritis woman : type identification subtype ESBL-producing strain screen synergy method , use disk contain 3rd generation cephalosporin , like cefotaxime , another disk contain β-lactamase inhibitor , clavulanic acid , accord recommendation competent authority antibiogram . The isolated strain analyse three main aspect : ( ) phylogenetic group determine multiplex PCR ( ii ) strain ' sequence-typing do use Multiple Sequence Typing ( iii ) presence 46 gene associate extra-intestinal virulence factor identify multiplex PCR . The determination ESBL type also do PCR . Detection cefoxitin resistant strain colonise gastrointestinal tract woman pyelonephritis treatment cefoxitin ; emergence resistance treatment determination associate mechanism resistance cefoxitin Screening enterobacteriaceae reduced-sensitivity cefoxitin do plat rectal swab ( stool sample ) DRIGALSKI medium contain 10 mg/l cefoxitin . Acquired resistance mechanism specie normally sensitive cefoxitin ( E. coli , Klebsiella spp . ) characterise : hyperproduction Amp C E. coli , hyperexpression efflux pump change purine E. coli et K. pneumoniae . If comparing strain necessary , do use ERIC2 PCR previously describe literature . Ethical aspects The research protocol present ethic committee , consent promoter obtain ( proof require insurance payment fee ) . The opinion committee include form deliver promoter competent authority begin study . All enrol patient require sign inform consent investigation treatment perform . The consent form keep 30 year CIC . Patients informed result completion study . Expected public health impact study The expected benefit use cefoxitin woman uncomplicated acute ESBL-producing E.coli pyelonephritis ( ) clinical microbiological effectiveness similar carbapenems ; ( ii ) decrease selection pressure bacteria colonise gastrointestinal tract , thus contribute prevent emergence carbapenemase-producing Enterobacteriaceae ( iii ) decrease drug-associated cost .</detailed_description>
	<mesh_term>Pyelonephritis</mesh_term>
	<mesh_term>Cefoxitin</mesh_term>
	<mesh_term>Cefotaxime</mesh_term>
	<criteria>Acute pyelonephritis without severity symptom positive urine culture ESBLproducing E. coli ( cefoxitinsensitive ) ; antibiotic treatment prescribe inclusion empirical treatment pyelonephritis , provide active vitro ESBLproducing E. coli strain . Presenting least functional sign urinary infection ( dysuria , cloudy urine , pain urination , pelvic lumbar pain ) Temperature &gt; 38 ° &lt; 36° infectious episode Imaging urinary way realize within ( echography ) 72 hour precede inclusion . Pregnant woman βlactam allergy ; antimicrobial therapy active vitro ESBLproducing E.coli pyelonephritis institute prior enrolment ; life expectancy &lt; 30 day ; creatinine clearance &lt; 30 ml/min ; patient guardianship without healthcare coverage . Sign sepsis severe septic shock Major cognitive confusion Patients refuse give consent form write Not membership national insurance scheme Universal Health Coverage ( CMU ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>antibiotic resistance</keyword>
	<keyword>E.coli</keyword>
	<keyword>cefoxitin</keyword>
	<keyword>pyelonephritis</keyword>
</DOC>